| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Dermatology [M. L., T. M., E-B. B.] and Pathology [M. N.], University of Würzburg Medical School, 97080 Würzburg, Germany; Immunex Corporation, Department of Protein Chemistry, Seattle, Washington 98101 [C. T. R.]; and Deutsches Krebsforschungszentrum Tumor Immunology Program, German Cancer Research Center, 69120 Heidelberg, Germany [P. H. K., H. W.]
 |
ABSTRACT |
|---|
 Top ABSTRACT IntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
|
Introduction |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
|
Materials and Methods |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Tissue Culture.
PK cultures were prepared from newborn foreskins as described
previously (12)
. Cells were kept in serum-free
keratinocyte growth medium (Cellsystems, St. Katharinen,
Germany) and used only up to passage 3 for all experiments. The
spontaneously TK line HacaT, SCL-1, and SCL-2 were kindly
provided by Dr. N. Fusenig (Deutsches Krebsforschungszentrum,
Heidelberg, Germany) and were cultured as described (13)
.
SCC12F cells were obtained and cultured as described elsewhere
(14)
.
Reverse Transcription-PCR.
RNA was prepared with Qiagen (Hilden, Germany) RnEasy Kit
according to the manufacturer’s recommendation. RNA was reverse
transcribed and the resulting cDNA was analyzed with 100 pmol of each
of the forward and reverse primer pairs (MWG Biotech, Munich, Germany)
for the presence of TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, and
ß-actin, yielding amplification products of 506, 502, 612, 453, and
219 bp, respectively. Primers and numbers of cycles used are described
in Table 1
. Samples in which reverse transcriptase was omitted were amplified for
40 cycles with ß-actin-specific primers to exclude genomic DNA
contamination. Setup experiments demonstrated exponential amplification
for cycle number and primer pairs used (data not shown).
|
with
denaturation (94°C, 1 min), primer annealing (55°C, 1 min), and DNA
polymerization (72°C, 1 min) and a final extension step of 7 min at
72°C. PCR products were electrophoresed on a 2.5% agarose gel,
stained with ethidium bromide, and photographed on an UV screen.
Western Blot Analysis.
Total cellular proteins were collected as described (15)
with the exception that Complete protease inhibitor cocktail
(Boehringer Mannheim, Mannheim, Germany) was used. A total of 20–75
µg of protein were electrophoresed on SDS-PAGE gels and transferred
to nitrocellulose membranes. Membranes were blocked and hybridization
was performed with Ab to PARP, caspase 8, caspase 3, or cFLIP.
After incubation with appropriate secondary Ab, bands were visualized
using the enhanced chemiluminescence detection kit (Amersham, Arlington
Heights, IL). Blots were subsequently rehybridized with anti-tubulin Ab
(Sigma, St. Louis, MO) to show equal loading of the gel.
FACScan Analysis.
Subconfluent TK or PK were detached from the plates by EDTA treatment
before brief treatment with trypsin. A total of 5 x 105 cells were resuspended in ice-cold PBS
containing 1% BSA (PBS/BSA) and reacted in 5 µg/ml
monoclonal Ab or isotyped control IgG and then in FITC-conjugated
secondary Ab. A total of 105 cells were analyzed
by FACScan (Becton Dickinson and Co., San Jose, CA).
Induction of Cell Death by Recombinant Human TRAIL or TRAIL-R1-
and TRAIL-R2-Specific Monoclonal Ab.
Preconfluent TK or PK were washed once with PBS and 1 ng–1 µg/ml
recombinant LZ-TRAIL or diluent alone was added. CHX and TRAIL were
added to the culture medium simultaneously. Cultures were maintained at
37°C until analysis. For induction of apoptosis with TRAIL-R1- and
TRAIL-R2-specific monoclonal Ab, 96-well plates were coated with the
indicated concentrations of the monoclonal Ab overnight at 4°C. Then
3 x 105 PK were added to wells
that were washed three times with PBS. After attachment for at
least 2 h, CHX (1 µg/ml) or diluent alone was added and cell
death was determined after a 16-h incubation.
Apoptosis and Cytotoxicity Assays.
Crystal violet staining of surviving attached cells was performed
16–24 h after addition of LZ-TRAIL, as described (16)
.
Briefly, cells were seeded in 24-well plates (1 x 105 cells) or in 96-well plates (2 x 104 cells) and treated as described in
"Results." Absorbance of eluted crystal violet was measured in an
ELISA reader at 570 nm. Parallel plates were examined by propidium
iodide staining and flow cytometrical analysis of subdiploid DNA
content as described (17)
. The percentage of apoptotic
nuclei was always >95% for conditions where viability was determined
as background (0%) in the cytotoxicity assay. In some experiments
apoptosis was determined by detection of internucleosomal DNA
fragmentation by cell death detection ELISA (Cell Death Detection ELISA
Plus, Boehringer Mannheim) used according to the manufacturer’s
instructions. Analysis of half-maximal response to TRAIL-induced
apoptosis was determined by nonlinear regression analysis.
Transient Transfection Assay for cFLIP.
Sixteen to thirty-six hours before transfection with Fugene (Boehringer
Mannheim), 5 x 105 HacaT cells
were seeded per well in six-well plates. Cells were cotransfected with
0.5 µg of pGREEN LANTERN-1 (Life Technologies, Inc., Eggenstein,
Germany) GFP expression vector (pGL) and increasing
amounts of pcDNA3-cFLIP vector (up to 0.5 µg; Ref. 9
).
The total amount of transfected DNA was kept constant to 1 µg DNA by
adding the appropriate amount of pcDNA3 control vector. After
transfection, the cells were incubated 24–36 h to permit recovery and
maximum expression (i.e., assessed by GFP expression). For
assessment of apoptosis in response to TRAIL, cultures were either
untreated or incubated with 50 ng/ml of LZ-TRAIL for an additional
16 h. Cell death was analyzed by determining the percentage of
propidium iodide-positive cells in the GFP-expressing
population.
|
Results |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
and cellular apoptosis was assayed by determination of
internucleosomal DNA fragmentation 16 h (Fig. 1B)
or
PARP cleavage 4 h (Fig. 1C)
after addition of LZ-TRAIL.
When compared with diluent-treated control cells, LZ-TRAIL-treated PK
as well as TK showed a marked reduction of survival, induction of
internucleosomal DNA fragmentation, and PARP cleavage, indicating that
TRAIL induces apoptosis in PK as well as TK cells. Reduction of
survival and induction of internucleosomal DNA fragmentation or PARP
cleavage was completely inhibited by ZVAD-fmk, which is known to block
the caspase family of proteases (19)
, suggesting that
TRAIL-mediated apoptosis in keratinocytes requires a
caspase-dependent signal transduction pathway (Fig. 1)
. However,
analysis of the dose response to TRAIL- induced apoptosis revealed
differential sensitivity of PK when compared with TK (Fig. 2)
. PK required 500 ng/ml of LZ-TRAIL for maximal killing, whereas TK
required only 100 ng/ml for the maximal cytotoxic effect. Therefore,
our data demonstrate that although at lower levels of TRAIL a
differential sensitivity between normal and transformed keratinocytes
can be detected, both cell types succumb to high levels of TRAIL.
|
|
. On the protein level, whereas PK strongly expressed
TRAIL-R1 and -R2, little if any surface expression of TRAIL-R3 and no
surface expression of TRAIL-R4 was detected. On the surface of TK,
expression of TRAIL-R1 and -R2 was detected, albeit to a lesser extent
than on the surface of PK, and no staining for TRAIL-R3 or -R4 was
detectable (Fig. 3B)
. Therefore, our data demonstrate that
both cell types exhibit a similar TRAIL receptor surface expression. To
further confirm that TRAIL-R3, TRAIL-R4, or OPG expression is not the
main regulatory mechanism against TRAIL-induced apoptosis in PK, we
compared treatment of PK with LZ-TRAIL or a combination of TRAIL-R1-
and TRAIL-R2-specific agonistic monoclonal Ab in the presence and
absence of CHX. This experiment allows for the direct differentiation
between a potential protective role of the non-death-inducing TRAIL-R3,
-R4, and OPG on the one hand and, on the other hand, intracellular
antiapoptotic mechanisms. Interestingly, in PK TRAIL-R1 and -R2
triggering induced dose-dependent apoptosis similar to that induced by
recombinant LZ-TRAIL. However, 10-fold higher concentrations of
Ab for similar killing efficiency were required when compared with
LZ-TRAIL, a fact that can be explained by different agonistic
activities of the monoclonal Ab and LZ-TRAIL, respectively (Fig. 3C)
. More importantly, the protein synthesis inhibitor CHX,
which has been shown to increase sensitivity to death ligand-induced
apoptosis (20)
, increased sensitivity to LZ-TRAIL or
TRAIL-R1 and TRAIL-R2 triggering (Fig. 3C)
, suggesting that
TRAIL-R3, TRAIL-R4, and/or OPG expression may not be the main mechanism
regulating TRAIL sensitivity in PK. Yet, these data point toward an
important role for intracellular signaling events in the regulation of
keratinocyte sensitivity and resistance to TRAIL.
|
but not in PK (Fig. 4B)
. However, when PK were
treated with LZ-TRAIL in the presence of CHX, caspase 8 and caspase 3
were strongly activated (Fig. 4B)
, which was similar to the
activation observed in TK. Concomitantly, in the presence of CHX, PK
were as sensitive as TK to LZ-TRAIL-induced apoptosis (Fig. 2)
. These
data were indicative of an early apical block of TRAIL-induced
apoptosis in PK compared with TK and led us to examine proteins known
to interfere with caspase 8 activation at the DISC level.
|
. To examine the influence of CHX treatment on
cFLIPL expression in PK, we analyzed PK treated
for different lengths of time with CHX for cFLIPL
expression. Interestingly, cFLIPL levels were
markedly reduced within 45–90 min and were barely detectable after
5 h, indicating that PK required active protein synthesis to
maintain cFLIPL protein levels (Fig. 4C)
. Moreover, three different squamous cell carcinoma lines
(SCC12F, SCL-1, and SCL-2) exhibited sensitivity to LZ-TRAIL-induced
apoptosis comparable with that of TK (data not shown) and contained
only low levels of cFLIPL as demonstrated by
Western blot analysis (Fig. 4D)
. Thus, our data indicate
that cFLIPL may act as an important regulator of
TRAIL-induced apoptosis in primary and malignant keratinocytes.
Overexpression of cFLIPL Decreases Sensitivity to
TRAIL.
To assess whether cFLIP may act as a regulator of sensitivity to
TRAIL-induced apoptosis in keratinocytes, we tested whether the ectopic
expression of cFLIPL influenced TRAIL sensitivity
of TK. As shown in Fig. 4E
, TK transfected with high or
intermediate amounts of cFLIP demonstrated a substantial reduction of
cell death when compared with vector-transfected controls. These
results indicate that cFLIP represents an important intracellular
regulator of resistance to TRAIL in keratinocytes (Fig. 4E)
.
|
Discussion |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Due to the fact that TRAIL-R3, TRAIL-R4, and OPG do not signal for cell death, it was proposed that these receptors might provide resistance to TRAIL (6 , 7 , 25) . Yet, this proposed function is rather speculative because thus far it has never been tested in nontransfected cells. When comparing the surface expression levels of the different TRAIL receptors on PK and TK, we found, albeit at low levels, TRAIL-R3 on the surface of PK but not on the surface of TK, whereas TRAIL-R4 was absent from the surface of both cell types despite strong mRNA expression. Another difference between the two cell types was higher expression of TRAIL-R1 and TRAIL-R2 on PK compared with expression on TK. It is currently not known how the different TRAIL-R interact with each other on the cell surface, nor is it known how much TRAIL-R3, TRAIL-R4, or OPG is needed under physiological conditions to potentially disrupt TRAIL-induced DISC formation. Although the stronger expression of TRAIL-R1 and -R2 on PK would rather lead to the prediction of higher sensitivity to TRAIL in these primary cells, we could not exclude that low expression of TRAIL-R3 on their surface might be responsible for mediating the observed relative resistance to TRAIL. To address this question in detail, we performed experiments that bypassed the potential effects of TRAIL-R3, TRAIL-R4, or OPG in PK by induction of apoptosis with specific monoclonal Ab to TRAIL-R1 and -R2. If the non-death-inducing TRAIL receptors played a role in mediating resistance to TRAIL in the primary cells, then TRAIL-R1- and TRAIL-R2-specific Ab should be able to induce apoptosis although TRAIL would not. Yet, dose dependency of PK apoptosis was similar between recombinant TRAIL and a mix of TRAIL-R1- and TRAIL-R2-specific Ab. Similarly, in PK the CHX-mediated sensitization to apoptosis was virtually identical for TRAIL-, TRAIL-R1-, and TRAIL-R2-induced cell death. These data clearly indicate that mainly intracellular regulators are responsible for the observed relative resistance of PK to TRAIL. In addition, we can conclude that the extracellular regulation of TRAIL sensitivity by TRAIL-R3, TRAIL-R4, or OPG plays a less important role, at least in keratinocytes.
To date, little is known about the signaling events associated with TRAIL receptor ligation. It is currently not known which adapter proteins are recruited to the TRAIL-R DISC under physiological conditions. However, overexpression of dominant negative forms of Fas-associated death domain (FADD) and TNF-associated death domain (TRADD) inhibited TRAIL-induced apoptosis (11 , 16 , 26) . Our data confirm previous findings in myeloma and melanoma cells and expand them to keratinocytes in as much as caspase 8 and caspase 3 are necessary for induction of TRAIL-induced apoptosis because inhibition of caspases completely abrogated their processing and TRAIL-induced apoptosis in keratinocytes (27 , 28) . Upon treatment with TRAIL in the presence of CHX, PK were as sensitive as TK. Concomitantly, TRAIL treatment led to similar activation of caspase 8 in both cell types, suggesting that in the absence of the protein synthesis inhibitor CHX an unidentified protein inhibits the cytotoxic TRAIL signal at a very early stage, namely prior to caspase 8 activation. cFLIPL is a protein known to interfere with the proximal death receptor-mediated cascade and has been shown to suppress CD95-, TNF-, and TRAIL-mediated apoptosis (23) . Furthermore, it was recently shown that cFLIPL inhibits caspase 8 activation at the CD95 DISC level (9) . Our data clearly show that cFLIPL is strongly expressed in PK and is undetectable in TK. Upon CHX treatment, cFLIPL levels decreased rapidly in PK, correlating with an increase in sensitivity to TRAIL. In addition, transient transfection of TRAIL-sensitive TK with cFLIPL rendered these cells resistant to TRAIL-mediated apoptosis. Therefore, it is tempting to speculate that the relative resistance of PK to TRAIL-induced apoptosis is conferred by cFLIPL. In fact, the analysis of a number of squamous cell carcinoma cell lines indicated that this phenomenon may be of fundamental importance because low levels of cFLIPL expression correlated well with TRAIL sensitivity in all cell lines tested.
If nonmelanoma skin cancer is not treated by surgery, it often leads to death due to metastasis. Common treatment regimens only have limited success for metastatic disease. Therefore, effective new therapeutic agents would be beneficial for the treatment of this disease. Indeed, induction of apoptosis via death receptors has been shown to represent one possible mechanism by which chemotherapeutic agents act on tumor cells (29) . Therefore, an attractive treatment option for cancer might be by direct activation of TRAIL receptors. Interestingly, it was recently shown that TRAIL exerts a potent antitumor activity in vivo without exhibiting any systemic toxicity (4) . Our data suggest that TRAIL may represent a useful option for the treatment of nonmelanoma skin cancer.
In summary, we first demonstrate a relative resistance to TRAIL-induced apoptosis of PK compared with TK. Then we show that TRAIL sensitivity is mainly regulated by intracellular factors protecting PK against the cytotoxic signal induced by TRAIL. Furthermore, high cFLIPL levels in PK correlated with inhibition of caspase 8 activation and decreased sensitivity to TRAIL, whereas low cFLIPL levels correlated with efficient caspase 8 activation and high TRAIL sensitivity in TK and squamous cell carcinomas. Additionally, ectopic expression of cFLIPL leads to TRAIL resistance of TK. Taken together, these data suggest an important role for cFLIPL in determining differential sensitivity of PK versus TK. This mechanism of resistance to TRAIL-mediated apoptosis indeed may be important in many different cellular systems.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was supported in part by grants from
Erweiterte Forschungsfoerderung des Freistaates Bayerm (Nr. 6 a) and a
grant from Interdisziplinaerem Zentrum fuer Klinische Forschung
Wuerzburg (IZKF 01 KS 9603, Z 4-14) (to M. L.). H. W. was supported
by the AIDS Stipend Program of the Bundesministerium für Bildung
und Forschung. 
2 To whom requests for reprints should be
addressed, at University of Würzburg Medical School, Department
of Dermatology, Josef-Schneider-Strasse 2, 97080 Würzburg,
Germany. Phone: 0931-201-2710; Fax: 0931-201-2700.
3 The abbreviations used are: TNF, tumor necrosis
factor; TRAIL, TNF-related apoptosis-inducing ligand; TRAIL-R, TRAIL
receptors; OPG, osteoprotegerin; PK, primary keratinocytes; TK,
transformed keratinocytes; ZVAD-fmk, z-Val-Ala-Asp-fluoromethyl ketone;
Ab, antibody; LZ-TRAIL, leucine zipper-TRAIL; PARP,
poly-ADP-ribose-polymerase; CHX, cycloheximide; DISC, death-inducing
signaling complex; cFLIPL, long form of cFLIP; GFP, green
fluorescence protein.
Received 9/17/99. Accepted 12/13/99.
|
REFERENCES |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
and by ultraviolet B radiation. J. Clin. Invest., 92: 462-470, 1993.
expression. J. Invest. Dermatol., 110: 353-357, 1998.[Medline]
B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7: 813-820, 1997.[Medline]
B. Immunity, 7: 831-836, 1997.[Medline]
This article has been cited by other articles:
|
|
 |
|
  S. Kato, A. Sadarangani, S. Lange, A. M. Delpiano, M. Vargas, J. Branes, J. Carvajal, S. Lipkowitz, G. I. Owen, and M. A. Cuello 2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts Reproductive Sciences, November 1, 2008; 15(9): 878 - 894. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Rong, J. H. Cai, and J. Andrews Cloning and apoptosis-inducing activities of canine and feline TRAIL Mol. Cancer Ther., July 1, 2008; 7(7): 2181 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Locklin, E. Federici, B. Espina, P. A. Hulley, R. G. G. Russell, and C. M. Edwards Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis Mol. Cancer Ther., December 1, 2007; 6(12): 3219 - 3228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Meslin, A. Hamai, P. Gao, A. Jalil, N. Cahuzac, S. Chouaib, and M. Mehrpour Silencing of Prion Protein Sensitizes Breast Adriamycin-Resistant Carcinoma Cells to TRAIL-Mediated Cell Death Cancer Res., November 15, 2007; 67(22): 10910 - 10919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Ullenhag, A. Mukherjee, N. F.S. Watson, A. H. Al-Attar, J. H. Scholefield, and L. G. Durrant Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients Clin. Cancer Res., September 1, 2007; 13(17): 5070 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Roue, P. Perez-Galan, M. Lopez-Guerra, N. Villamor, E. Campo, and D. Colomer Selective Inhibition of I{kappa}B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level J. Immunol., February 1, 2007; 178(3): 1923 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shi, Y. Liu, Y. Zheng, Y. Guo, J. Zhang, P.-t. Cheung, R. Xu, and D. Zheng Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice Cancer Res., December 15, 2006; 66(24): 11946 - 11953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gong, D. Yang, S. Kohanim, R. Humphreys, L. Broemeling, and R. Kurzrock Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies Mol. Cancer Ther., December 1, 2006; 5(12): 2991 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Braeuer, C. Buneker, A. Mohr, and R. M. Zwacka Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells Mol. Cancer Res., October 1, 2006; 4(10): 715 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jalving, S. de Jong, J. J. Koornstra, W. Boersma-van Ek, N. Zwart, J. Wesseling, E. G.E. de Vries, and J. H. Kleibeuker TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas. Clin. Cancer Res., July 15, 2006; 12(14): 4350 - 4356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Mundt, T Wirth, L Zender, M Waltemathe, C Trautwein, M P Manns, F Kuhnel, and S Kubicka Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake Gut, November 1, 2005; 54(11): 1590 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bremer, D. F. Samplonius, M. Peipp, L. van Genne, B.-J. Kroesen, G. H. Fey, M. Gramatzki, L. F.M.H. de Leij, and W. Helfrich Target Cell-Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7 Cancer Res., April 15, 2005; 65(8): 3380 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bremer, D. F. Samplonius, L. van Genne, M. H. Dijkstra, B. J. Kroesen, L. F. M. H. de Leij, and W. Helfrich Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR J. Biol. Chem., March 18, 2005; 280(11): 10025 - 10033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsuda, A. Almasan, M. Tomita, J.-n. Uchihara, M. Masuda, K. Ohshiro, N. Takasu, H. Yagita, T. Ohta, and N. Mori Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines J. Virol., February 1, 2005; 79(3): 1367 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-G. Jin, A. Kurakin, N. Benhaga, K. Abe, M. Mohseni, F. Sandra, K. Song, B. K. Kay, and R. Khosravi-Far Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5 J. Biol. Chem., December 31, 2004; 279(53): 55594 - 55601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wachter, M. Sprick, D. Hausmann, A. Kerstan, K. McPherson, G. Stassi, E.-B. Brocker, H. Walczak, and M. Leverkus cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-{kappa}B Activation at the Death-inducing Signaling Complex in Human Keratinocytes J. Biol. Chem., December 17, 2004; 279(51): 52824 - 52834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Marconi, P. Atzei, C. Panza, C. Fila, R. Tiberio, F. Truzzi, T. Wachter, M. Leverkus, and C. Pincelli FLICE/caspase-8 activation triggers anoikis induced by {beta}1-integrin blockade in human keratinocytes J. Cell Sci., November 15, 2004; 117(24): 5815 - 5823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Riley, J. M. Heeley, A. H. Wyman, E. L. Schlichting, and K. H. Moley TRAIL and KILLER Are Expressed and Induce Apoptosis in the Murine Preimplantation Embryo Biol Reprod, September 1, 2004; 71(3): 871 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kreuz, D. Siegmund, J.-J. Rumpf, D. Samel, M. Leverkus, O. Janssen, G. Hacker, O. Dittrich-Breiholz, M. Kracht, P. Scheurich, et al. NF{kappa}B activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP J. Cell Biol., August 2, 2004; 166(3): 369 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mezzanzanica, E. Balladore, F. Turatti, E. Luison, P. Alberti, M. Bagnoli, M. Figini, A. Mazzoni, F. Raspagliesi, M. Oggionni, et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma Clin. Cancer Res., August 1, 2004; 10(15): 5202 - 5214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Deeb, H. Jiang, X. Gao, M. S. Hafner, H. Wong, G. Divine, R. A. Chapman, S. A. Dulchavsky, and S. C. Gautam Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-{kappa}B through suppression of I{kappa}B{alpha} phosphorylation Mol. Cancer Ther., July 1, 2004; 3(7): 803 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Matsuyama, M. Yamamoto, I. Higashimoto, K.-i. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus Blood, July 1, 2004; 104(1): 184 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Pritzker, M. Scatena, and C. M. Giachelli The Role of Osteoprotegerin and Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Human Microvascular Endothelial Cell Survival Mol. Biol. Cell, June 1, 2004; 15(6): 2834 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Schmitz, H. Weyd, A. Krueger, S. Baumann, S. C. Fas, P. H. Krammer, and S. Kirchhoff Resistance of Short Term Activated T Cells to CD95-Mediated Apoptosis Correlates with De Novo Protein Synthesis of c-FLIPshort J. Immunol., February 15, 2004; 172(4): 2194 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harper, M. A. Hughes, S. N. Farrow, G. M. Cohen, and M. MacFarlane Protein Kinase C Modulates Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Targeting the Apical Events of Death Receptor Signaling J. Biol. Chem., November 7, 2003; 278(45): 44338 - 44347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Song, D. K. Song, M. Herlyn, K. C. Petruk, and C. Hao Cisplatin Down-Regulation of Cellular Fas-associated Death Domain-like Interleukin-1{beta}-converting Enzyme-like Inhibitory Proteins to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Melanoma Cells Clin. Cancer Res., September 15, 2003; 9(11): 4255 - 4266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leverkus, A. D. McLellan, M. Heldmann, A. O. Eggert, E.-B. Brocker, N. Koch, and E. Kampgen MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways Int. Immunol., August 1, 2003; 15(8): 993 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leverkus, M. R. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E.-B. Brocker, M. Goebeler, M. Neumann, and H. Walczak Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation Mol. Cell. Biol., February 1, 2003; 23(3): 777 - 790. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. W. Xiao, X. Yan, Y. Li, S. A. G. Reddy, and B. K. Tsang Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor {alpha} Is a Consequence of Nuclear Factor {kappa}B-Mediated Induction of Fas-Associated Death Domain-Like Interleukin-1{beta}-Converting Enzyme-Like Inhibitory Protein Endocrinology, February 1, 2003; 144(2): 623 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ursini-Siegel, W. Zhang, A. Altmeyer, E. N. Hatada, R. K. G. Do, H. Yagita, and S. Chen-Kiang TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis J. Immunol., November 15, 2002; 169(10): 5505 - 5513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Eid, R. W. Lewis, and M. V. Kumar Mifepristone Pretreatment Overcomes Resistance of Prostate Cancer Cells to Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand (TRAIL) Mol. Cancer Ther., August 1, 2002; 1(10): 831 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dorothee, I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-{alpha} on APO2L/TRAIL Expression and -Mediated Cytotoxicity J. Immunol., July 15, 2002; 169(2): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Griffith, J. M. Fialkov, D. L. Scott, T. Azuhata, R. D. Williams, N. R. Wall, D. C. Altieri, and A. D. Sandler Induction and Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand-mediated Apoptosis in Renal Cell Carcinoma Cancer Res., June 1, 2002; 62(11): 3093 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fotin-Mleczek, F. Henkler, D. Samel, M. Reichwein, A. Hausser, I. Parmryd, P. Scheurich, J. A. Schmid, and H. Wajant Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8 J. Cell Sci., January 7, 2002; 115(13): 2757 - 2770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frese, T. Brunner, M. Gugger, A. Uduehi, and R. A. Schmid Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Jazirehi, C.-P. Ng, X.-H. Gan, G. Schiller, and B. Bonavida Adriamycin Sensitizes the Adriamycin-resistant 8226/Dox40 Human Multiple Myeloma Cells to Apo2L/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated (TRAIL) Apoptosis Clin. Cancer Res., December 1, 2001; 7(12): 3874 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Southall, J. S. Isenberg, H. Nakshatri, Q. Yi, Y. Pei, D. F. Spandau, and J. B. Travers The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) alpha and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-kappa B-dependent Process J. Biol. Chem., November 30, 2001; 276(49): 45548 - 45554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Higuchi, S. F. Bronk, Y. Takikawa, N. Werneburg, R. Takimoto, W. El-Deiry, and G. J. Gores The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis J. Biol. Chem., October 12, 2001; 276(42): 38610 - 38618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Tollefson, K. Toth, K. Doronin, M. Kuppuswamy, O. A. Doronina, D. L. Lichtenstein, T. W. Hermiston, C. A. Smith, and W. S. M. Wold Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus Proteins J. Virol., October 1, 2001; 75(19): 8875 - 8887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kagawa, C. He, J. Gu, P. Koch, S.-J. Rha, J. A. Roth, S. A. Curley, L. C. Stephens, and B. Fang Antitumor Activity and Bystander Effects of the Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Gene Cancer Res., April 1, 2001; 61(8): 3330 - 3338. [Abstract] [Full Text]
|
|
|
|
|
|
N. Droin, F. Bichat, C. Rebe, A. Wotawa, O. Sordet, A. Hammann, R. Bertrand, and E. Solary Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells Blood, March 15, 2001; 97(6): 1835 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Miura, N. Misawa, N. Maeda, Y. Inagaki, Y. Tanaka, M. Ito, N. Kayagaki, N. Yamamoto, H. Yagita, H. Mizusawa, et al. Critical Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) to Apoptosis of Human Cd4+T Cells in HIV-1-Infected Hu-Pbl-Nod-Scid Mice J. Exp. Med., March 5, 2001; 193(5): 651 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hao, F. Beguinot, G. Condorelli, A. Trencia, E. G. Van Meir, V. W. Yong, I. F. Parney, W. H. Roa, and K. C. Petruk Induction and Intracellular Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Mediated Apotosis in Human Malignant Glioma Cells Cancer Res., February 1, 2001; 61(3): 1162 - 1170. [Abstract] [Full Text]
|
|
|
|
|
|
A. Eggert, M. A. Grotzer, T. J. Zuzak, B. R. Wiewrodt, R. Ho, N. Ikegaki, and G. M. Brodeur Resistance to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Neuroblastoma Cells Correlates with a Loss of Caspase-8 Expression Cancer Res., February 1, 2001; 61(4): 1314 - 1319. [Abstract] [Full Text]
|
|
|
|
|
|
R. Nimmanapalli, M. Porosnicu, D. Nguyen, E. Worthington, E. O’Bryan, C. Perkins, and K. Bhalla Cotreatment with STI-571 Enhances Tumor Necrosis Factor {{alpha}}-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells Clin. Cancer Res., February 1, 2001; 7(2): 350 - 357. [Abstract] [Full Text]
|
|
|
|
|
|
R. Nimmanapalli, C. L. Perkins, M. Orlando, E. O’Bryan, D. Nguyen, and K. N. Bhalla Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels Cancer Res., January 1, 2001; 61(2): 759 - 763. [Abstract] [Full Text]
|
|
|
|
|
|
W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al. Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617. [Abstract] [Full Text]
|
|
|
|
|
|
J. Wen, N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington, and K. Bhalla Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells Blood, December 1, 2000; 96(12): 3900 - 3906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leverkus, H. Walczak, A. McLellan, H.-W. Fries, G. Terbeck, E.-B. Brocker, and E. Kampgen Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis Blood, October 1, 2000; 96(7): 2628 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Griffith, R. D. Anderson, B. L. Davidson, R. D. Williams, and T. L. Ratliff Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis J. Immunol., September 1, 2000; 165(5): 2886 - 2894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wajant, E. Haas, R. Schwenzer, F. Muhlenbeck, S. Kreuz, G. Schubert, M. Grell, C. Smith, and P. Scheurich Inhibition of Death Receptor-mediated Gene Induction by a Cycloheximide-sensitive Factor Occurs at the Level of or Upstream of Fas-associated Death Domain Protein (FADD) J. Biol. Chem., August 4, 2000; 275(32): 24357 - 24366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nesterov, X. Lu, M. Johnson, G. J. Miller, Y. Ivashchenko, and A. S. Kraft Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis J. Biol. Chem., March 30, 2001; 276(14): 10767 - 10774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bernard, B. Quatannens, B. Vandenbunder, and C. Abbadie Rel/NF-kappa B Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1 J. Biol. Chem., July 13, 2001; 276(29): 27322 - 27328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Burns and W. S. El-Deiry Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach J. Biol. Chem., October 5, 2001; 276(41): 37879 - 37886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harper, S. N. Farrow, A. Kaptein, G. M. Cohen, and M. MacFarlane Modulation of Tumor Necrosis Factor Apoptosis-inducing Ligand- induced NF-kappa B Activation by Inhibition of Apical Caspases J. Biol. Chem., September 7, 2001; 276(37): 34743 - 34752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Simon, O. Williams, J. Mongkolsapaya, B. Jin, X. N. Xu, H. Walczak, and G. R. Screaton Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes PNAS, April 24, 2001; 98(9): 5158 - 5163. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
) or TK (
) were treated for 24 h with increasing
concentrations of LZ-TRAIL in the absence (open symbols) or
presence (filled symbols) of 1 µg/ml CHX and subsequently
were analyzed by crystal violet staining. Mean and SD of four
independent experiments are shown as a percentage of control. Surviving
cells are dose dependently decreased in PK as well as in TK.
Half-maximal responses to TRAIL were determined by nonlinear regression
analysis. PK require 143 ng/ml LZ-TRAIL, whereas TK cells require 32
ng/ml LZ-TRAIL for half-maximal cytotoxicity. Upon addition of CHX,
dose-response curves in PK as well as in TK are shifted to lower
concentrations of TRAIL with half-maximal cytotoxicity reached at 14
ng/ml LZ-TRAIL in PK and 7 ng/ml in TK, respectively.
